Last reviewed · How we verify
Propofol 1 % Injectable Suspension — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Propofol 1 % Injectable Suspension (Propofol 1 % Injectable Suspension) — Sindh Institute of Urology and Transplantation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Propofol 1 % Injectable Suspension TARGET | Propofol 1 % Injectable Suspension | Sindh Institute of Urology and Transplantation | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Propofol 1 % Injectable Suspension CI watch — RSS
- Propofol 1 % Injectable Suspension CI watch — Atom
- Propofol 1 % Injectable Suspension CI watch — JSON
- Propofol 1 % Injectable Suspension alone — RSS
Cite this brief
Drug Landscape (2026). Propofol 1 % Injectable Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/propofol-1-injectable-suspension. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab